Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2005

View Archived Issues

IDO - a target for anti-HIV therapy

H-1152: superior bronchodilatory potency and suggested safety for anesthesia in asthmatics

Further evidence that TRPV1 antagonism alleviates bone cancer pain

Enrollment completed in phase IIb HCV study of Albuferon plus ribavirin

ID Biomedical updates progress of two key vaccine programs

Idera studies HYB-2055 in combination with gemcitabine and carboplatin

Encouraging results for QR-442 in multiple sclerosis mouse model

Cerimon acquires U.S. rights to topical diclofenac formulations

Bayer and Ortho-McNeil enter agreement for BAY-59-7939

AT-1001 completes phase I study, receives fast track designation

Chiron begins phase I/II study of cell culture-derived influenza vaccine

Indevus begins phase III of PRO-2000 to prevent STDs

Novelos Therapeutics to hold end-of-phase II meeting for NOV-002

Vion offers pipeline progress report

JNJ-7706621 possesses dual inhibitory activity against CDKs and Aurora kinases

Immunomodulatory agents described in Novartis patents

Novel inhibitor of sphingolipid synthesis opens a new approach for anti-HCV drug design

Recent patents disclose novel agents for the treatment of diabetes

New agents claimed for the treatment of metabolic disorders

Aptivus for HIV receives European approval

Xolair approved in Europe

Noxafil approved in E.U. for invasive fungal infections

TNX-355 reported effective in reducing viral load of HIV-infected patients

Update on pimecrolimus in the treatment of skin disorders

Studies highlight antidepressant efficacy and other benefits of agomelatine

Study reveals how adiponectin may influence survival and longevity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...